IRadimed Corp.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US46266A1097
USD
101.69
2 (2.01%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Artivion, Inc.
IRadimed Corp.
BioLife Solutions, Inc.
Varex Imaging Corp.
Treace Medical Concepts, Inc.
Silk Road Medical, Inc.
OrthoPediatrics Corp.
Atrion Corp.
Cytek Biosciences, Inc.
Nevro Corp.
Minerva Surgical, Inc.

Why is IRadimed Corp. ?

1
High Management Efficiency with a high ROE of 17.02%
2
Company has a low Debt to Equity ratio (avg) at times
3
Healthy long term growth as Operating profit has grown by an annual rate 94.60%
4
The company has declared Positive results for the last 4 consecutive quarters
  • NET SALES(Q) Highest at USD 22.69 MM
  • RAW MATERIAL COST(Y) Fallen by 1.42% (YoY)
  • DIVIDEND PER SHARE(HY) Highest at USD 0
5
With ROE of 23.76%, it has a fair valuation with a 13.74 Price to Book Value
  • The stock is trading at a premium compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 93.88%, its profits have risen by 16.9% ; the PEG ratio of the company is 3.5
6
High Institutional Holdings at 64.22%
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
7
Market Beating performance in long term as well as near term
  • Along with generating 93.88% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to IRadimed Corp. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is IRadimed Corp. for you?

Medium Risk, High Return

Absolute
Risk Adjusted
Volatility
IRadimed Corp.
93.88%
3.85
36.21%
S&P 500
18.81%
0.98
19.26%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
21.45%
EBIT Growth (5y)
94.60%
EBIT to Interest (avg)
14.28
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.56
Sales to Capital Employed (avg)
0.86
Tax Ratio
20.79%
Dividend Payout Ratio
38.86%
Pledged Shares
0
Institutional Holding
64.22%
ROCE (avg)
58.93%
ROE (avg)
17.02%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
58
Industry P/E
Price to Book Value
13.74
EV to EBIT
47.76
EV to EBITDA
45.33
EV to Capital Employed
28.73
EV to Sales
14.90
PEG Ratio
3.51
Dividend Yield
0.84%
ROCE (Latest)
60.17%
ROE (Latest)
23.76%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

8What is working for the Company
NET SALES(Q)

Highest at USD 22.69 MM

RAW MATERIAL COST(Y)

Fallen by 1.42% (YoY

DIVIDEND PER SHARE(HY)

Highest at USD 0

OPERATING PROFIT(Q)

Highest at USD 7.71 MM

PRE-TAX PROFIT(Q)

Highest at USD 7.79 MM

NET PROFIT(Q)

Highest at USD 6.44 MM

EPS(Q)

Highest at USD 0.5

-4What is not working for the Company
DEBT-EQUITY RATIO (HY)

Highest at -54.07 %

INVENTORY TURNOVER RATIO(HY)

Lowest at 0 times

DEBTORS TURNOVER RATIO(HY)

Lowest at 0 times

Here's what is working for IRadimed Corp.

Net Sales
Highest at USD 22.69 MM and Grown
In each period in the last five periods
MOJO Watch
Near term sales trend is very positive

Net Sales (USD MM)

Operating Profit
Highest at USD 7.71 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (USD MM)

Pre-Tax Profit
Highest at USD 7.79 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit
Highest at USD 6.44 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (USD MM)

EPS
Highest at USD 0.5
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Dividend per share
Highest at USD 0
in the last five years
MOJO Watch
Company is distributing higher dividend from profits generated

DPS (USD)

Raw Material Cost
Fallen by 1.42% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for IRadimed Corp.

Debt-Equity Ratio
Highest at -54.07 % and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Inventory Turnover Ratio
Lowest at 0 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Debtors Turnover Ratio
Lowest at 0 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio